Statement of Changes in Beneficial Ownership (4)

FORM 4

[X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden
hours per response...

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Maslowski John Michael	2. Issuer Name and Ticker or Trading Symbol Fibrocell Science, Inc. [ FCSC ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) CEO
(Last)          (First)          (Middle) FIBROCELL SCIENCE, INC., 405 EAGLEVIEW BOULEVARD	3. Date of Earliest Transaction (MM/DD/YYYY) 12/13/2019
(Street) EXTON, PA 19341 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/13/2019		D		3164	D	$3 (1)	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$232.5	12/13/2019		D			908	(2)	1/14/2021	Common Stock	908.0	(2)	0	D
Option to Purchase Common Stock	$82.35	12/13/2019		D			1167	(2)	7/19/2023	Common Stock	1167.0	(2)	0	D
Option to Purchase Common Stock	$74.25	12/13/2019		D			1334	(2)	1/17/2024	Common Stock	1334.0	(2)	0	D
Option to Purchase Common Stock	$44.1	12/13/2019		D			1334	(2)	5/13/2024	Common Stock	1334.0	(2)	0	D
Option to Purchase Common Stock	$52.95	12/13/2019		D			6668	(2)	1/20/2025	Common Stock	6668.0	(2)	0	D
Option to Purchase Common Stock	$34.05	12/13/2019		D			6667	(2)	3/1/2026	Common Stock	6667.0	(2)	0	D
Option to Purchase Common Stock	$9.94	12/13/2019		D			16667	(2)	12/16/2026	Common Stock	16667.0	(2)	0	D
Option to Purchase Common Stock	$3.45	12/13/2019		D			20000	(2)	1/25/2028	Common Stock	20000.0	(2)	0	D
Option to Purchase Common Stock	$1.78	12/13/2019		D			100000	(2)	4/12/2029	Common Stock	100000.0	(2)	0	D

Explanation of Responses:
(1)	Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the "Merger Agreement"), among Fibrocell Science, Inc. (the "Company"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00.
(2)	Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Maslowski John Michael FIBROCELL SCIENCE, INC. 405 EAGLEVIEW BOULEVARD EXTON, PA 19341	X		CEO

Signatures
/s/ John M. Maslowski		12/13/2019
**Signature of Reporting Person		Date